Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Bain Capital Life Sciences entities reported a 4.3% passive ownership stake in Pharvaris N.V. ordinary shares. As of December 31, 2025, Bain Capital Life Sciences Fund I held 1,640,817 shares (about 2.5% of the class), BCIP Life Sciences Associates held 167,950 shares (about 0.3%), and Bain Capital Life Sciences Opportunities III held 993,314 shares (about 1.5%). These holdings total 2,802,081 shares, calculated using 64,959,454 Pharvaris ordinary shares outstanding as of September 30, 2025. The group certifies the shares are not held to change or influence control of Pharvaris, indicating a passive investment stance.
Pharvaris updated its 2026 plan for deucrictibant, its oral bradykinin B2 receptor antagonist for hereditary and acquired angioedema. The company expects topline Phase 3 data from the CHAPTER-3 prophylaxis study in the third quarter of 2026 and is progressing enrollment in the long-term CHAPTER-4 extension. For on-demand treatment of hereditary angioedema attacks, the pivotal RAPIDe-3 Phase 3 trial met its primary and all secondary endpoints, with a median time to onset of symptom relief of 1.28 hours versus placebo, and Pharvaris aims to file a U.S. New Drug Application in the first half of 2026, using RAPIDe-2 and RAPIDe-3 as the basis. The CREAATE Phase 3 study in acquired angioedema due to C1 inhibitor deficiency is underway, assessing both prophylactic and on-demand use. Management estimates its cash runway extends into the first half of 2027 and notes recent inclusion in the Nasdaq Biotechnology Index.
Pharvaris N.V. submitted a Form 6-K summarizing that it has furnished a press release reporting financial results and other business updates for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is designated as furnished, not filed, under the Exchange Act. The filing also attaches Management’s Discussion and Analysis as Exhibit 99.2 and unaudited condensed consolidated interim financial statements as Exhibit 99.3 for the same periods and as of December 31, 2024. Exhibits 99.2 and 99.3 are incorporated by reference into Pharvaris’s existing Form F-3 and Form S-8 registration statements.
Pharvaris N.V. filed a post-effective amendment to its Form F-3 registration statement to register an additional 6,045,155 ordinary shares (including 500,000 newly registered shares) for resale by a selling securityholder and updated the base prospectus and exhibits accordingly. The filing discloses clinical development progress for deucrictibant: the global Phase 3 RAPIDe-3 on-demand study (20 mg IR capsule) is enrolling with ~120 participants and topline data expected in Q4 2025, and the Phase 3 CHAPTER-3 prophylaxis study (40 mg/day XR) aims to enroll ~81 participants with topline data expected in H2 2026. The FDA previously lifted IND clinical holds after review of a 26-week rodent toxicology study.
Pharvaris N.V. filed a post-effective amendment to its Form F-3 registration statement to register an additional 6,045,155 ordinary shares (including 500,000 newly registered shares) for resale by a selling securityholder and updated the base prospectus and exhibits accordingly. The filing discloses clinical development progress for deucrictibant: the global Phase 3 RAPIDe-3 on-demand study (20 mg IR capsule) is enrolling with ~120 participants and topline data expected in Q4 2025, and the Phase 3 CHAPTER-3 prophylaxis study (40 mg/day XR) aims to enroll ~81 participants with topline data expected in H2 2026. The FDA previously lifted IND clinical holds after review of a 26-week rodent toxicology study.
Pharvaris N.V. filed a Form 6-K furnishing a Registration Rights Agreement dated September 2, 2025. The filing states the 6-K is incorporated by reference into the companys registration statements on Form F-3 (registration numbers 333-273757, 333-277705 and 333-278650) and Form S-8 (registration number 333-252897). The document is signed on September 8, 2025 by Berndt Modig, Chief Executive Officer. The filing otherwise consists of the exhibit reference and standard Form 6-K incorporation language.
Pharvaris N.V. Schedule 13G/A discloses that a group of Venrock-related entities and two individuals beneficially own an aggregate of 2,047,620 ordinary shares of Pharvaris, representing 3.8% of the class as of June 30, 2025. The filing breaks this down as 380,109 shares held by Venrock Healthcare Capital Partners III, L.P., 38,028 by VHCP Co-Investment Holdings III, LLC, and 1,629,483 by Venrock Healthcare Capital Partners EG, L.P. The 3.8% percentage is calculated using 54,493,142 ordinary shares outstanding per the issuer's prospectus supplement dated July 22, 2025 (filed July 24, 2025). All entity filers are organized in Delaware; Nimish Shah and Bong Koh are U.S. citizens. The filing is signed on behalf of the reporting persons by Sherman G. Souther (authorized signatory) on August 14, 2025, and includes a certification that the securities were not acquired to influence control of the issuer.